Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer Authors: Ou Deng, Thales Da Costa Nepomuceno, Bin Fang, Eric A. Welsh, Victoria Izumi, Rachael H. Martin, Erin M. George, John M. Koomen, Alvaro N. Monteiro, Uwe Rix, Giovanni Nassa, Giovanni Nassa, Giovanni Nassa, Giovanni Nassa Published: 2026 ABSTRACT Ovarian cancer remains a leading cause of gynecologic cancer–related deaths worldwide. Deficiencies in BRCA1/2 are well-established biomarkers that predict sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPis). However, emerging evidence indicates that a subset of BRCA-proficient tumors also responds to PARPi therapy, suggesting the presence of additional molecular mechanisms. We hypothesized that the composition of the PARP1 protein complex and PARylation-mediated signaling contribute to PARPi response in BRCA-proficient HGSOC. We assessed PARPi response across a panel of BRCA-proficient ovarian cancer cell lines and identified distinct sensitive and resistant groups. Chemical proteomics with rucaparib revealed different PARP1 complexes including higher enrichment of MSH6 in sensitive cells. Co-immunoprecipitation analyses further confirmed differential assembly of PARP1–MSH6–PARP2 complexes between sensitive and resistant models. To explore PARylation signaling, we performed ADP-ribosylation proteomics using clickable NAD⁺ analogs, revealing distinct PARylation profiles between sensitive and resistant cell lines. CHAF1A, a known MSH6 interactor and PARP1 substrate, showed more pronounced reduction in ADP-ribosylation in PARPi-sensitive cells. Targeting MSH6 using CRISPR or siRNA decreased PARPi sensitivity. In addition, mTOR signaling was reduced in sensitive, but increased in resistant cells, following rucaparib treatment. Notably, MSH6 knockdown led to increased CHAF1A expression regardless of rucaparib treatment. Importantly, knockdown of CHAF1A significantly impaired cell viability, especially in A2780 cells, and suppressed mTOR signaling, suggesting that CHAF1A acts downstream of MSH6 to regulate the mTOR axis. Furthermore, co-treatment with mTORC1 inhibitors enhanced the cellular effects of rucaparib in resistant cells, suggesting a therapeutic potential of targeting downstream mTOR effectors to overcome intrinsic resistance. In conclusion, this study identifies the PARP1–MSH6 interaction to modulate PARPi sensitivity via CHAF1A-mTOR signaling in BRCA-proficient ovarian cancer. By integrating chemical proteomics and ADP-ribosylation proteomics, we delineate the interplay between PARP1 complex composition and signaling dynamics, highlighting MSH6 as a critical modulator of PARPi response and potential biomarker to enhance therapeutic efficacy in BRCA-proficient HGSOC. Introduction Ovarian cancer (OC) remains one of the most lethal gynecological malignancies [1–3]. Poly(ADP-ribose) polymerase inhibitors (PARPis) have significantly improved outcomes for patients with homologous recombination repair (HR) deficiency (HRD), largely due to loss-of-function mutations in the BRCA1 and BRCA2 genes [4–6]. However, emerging evidence indicates that some patients with BRCA-proficient ovarian cancers can also benefit from PARPi therapy [7–10]. Although HRD has been implicated in some cases [9,11,12], additional mechanisms have been reported, including replicative gap accumulation [13–15], alterations in DNA damage response signaling [16,17], and SLFN11 expression [18,19]. Notably, the underlying mechanisms and appropriate biomarkers remain incompletely understood. However, a deeper mechanistic understanding of PARPi sensitivity and inherent resistance in BRCA-proficient OC may reveal novel cellular vulnerabilities and drug targets that could be harnessed to develop drug combination therapies that either enhance efficacy in PARPi-sensitive tumors or overcome inherent PARPi-resistance. Furthermore, this may identify additional biomarkers for patients that may be missed by BRCA/HRD testing. In our previous work, we have observed that the composition of PARP1-associated protein complexes and patterns of poly-ADP-ribosylation (PARylation) may play critical roles in differentially modulating PARPi response between BRCA-deficient and BRCA-proficient OC cells [20]. However, despite these insights, comprehensive studies systematically exploring these protein interactions in BRCA-proficient OC to differentiate PARPi-sensitive from -resistant tumors are needed. In this study, we investigated the proteomic landscape associated with PARPi sensitivity in a diverse panel of BRCA-proficient OC cell lines, defined here by the absence of BRCA1/2 mutations or genomic deletions. Most cell lines used in this study have previously been reported to exhibit HR proficiency [21–24]. We applied chemical proteomics and ADP-ribosylation proteomics to identify key PARP1-interacting complexes and downstream PARylation-dependent signaling pathways that correlate with differential drug response. Our findings expand the current understanding of PARPi activity beyond canonical HR deficiency, highlighting novel biomarker candidates and therapeutic vulnerabilities that may inform personalized treatment strategies and broaden the clinical utility of PARPis in ovarian cancer. Preliminary findings from this study were previously presented in abstract form [25]. Materials and methods Cell lines and cell culture All cell lines were maintained in a humidified incubator at 37 °C with 5% CO2. A2780 [26], HEYA8 [27], OVCA433 [28], OVCA432 [28], DOV13, Caov3 [29], OVCAR3, OVCAR8 [30] were cultured in RPMI 1640 with 10% fetal bovine serum (FBS, Gibco). SKOV3 were cultured in ATCC-formulated McCoy's 5a Medium Modified (ATCC 30–2007) with 10% FBS. FU-OV1 [31] and iFTEC282P53R175H were cultured in DMEM/F12 (Wisent) with 10% FBS. UWB+BRCA1 cells were incubated in 1:1 MEBM Bullet Kit and RPMI1640 media (Lonza) supplemented with 3% fetal bovine serum and 200 μg/ml G418 (Life Technologies, Inc). PEO4 were cultured in RPMI 1640 with 10% FBS, 4 mM L-Glutamine and 10 mM HEPES. UWB1.289 + BRCA1 (UWB+BRCA1, ATCC CRL-2946) cell lines and SKOV3 (ATCC HTB-77) were purchased from American Type Culture Collection (ATCC). The OVCAR3 (Cat. No. SCC257) and DOV13 (Cat. No. SCC186) cell lines were obtained from Millipore Sigma. PEO4 was a gift from Dr. Andrew Godwin (University of Kansas Medical Center). A2780, OVCAR8 and HEYA8 were gifts from Dr. Guillermo Armaiz (Ponce Health Sciences University). OVCA433, OVCA432, FU-OV1 and Caov3 were gifts from Dr. Anthony Magliocco (Moffitt Cancer Center). Cell line identity was confirmed by short tandem repeat (STR) profiling prior to experimentation. iFTE282 (Tert-immortalized fallopian tube epithelial cells expressing mutant p53) cells were gift from Simon Gayther (Cedars-Sinai Medical Center), originally generated and described previously [32]. Cells were routinely tested for mycoplasma contamination and confirmed to be negative. Compounds Olaparib (AZD2281; Chemietek), niraparib (MK4827; Chemietek), rucaparib (AG014699; Chemietek), rapamycin (CeMM), Everolimus (CeMM) and LY2584702 (Selleckchem) were dissolved in DMSO at a concentration of 10 mM and stored at −20 °C. 6-alkyne (6Yn)- and 2-alkyne (2Yn)-adenosine probes were synthesized in-house by the chemistry unit of the Chemical Biology Core of the Moffitt Cancer Center according to published procedures [20,33]. Drug dilutions were made in DMSO. Immunoblotting Cells were harvested from culture plates, washed three times with ice-cold PBS, and lysed in buffer containing 0.4% NP40, as previously described [20]. The lysates were precleared twice by centrifugation at 27,000 x g at 4 °C for 20 min and protein concentration was determined using standard Bradford assay. Proteins were resolved by SDS-PAGE, transferred to activated polyvinylidene difluoride membranes using the TransBlot Turbo system (Bio-Rad), incubated at 4 °C overnight with primary antibodies, and washed with Tris-buffered saline with Tween-20, followed by 1 h incubation with secondary antibodies at room temperature (RT). Signals were developed with Clarity Western ECL Substrate (Bio-Rad, 1705061) and read on an Odyssey FC Imager using Image studio software (Licor). Antibodies used were against MSH6 (#PIMA532676, Fisher Scientific), PARP1 (#9542S, Cell Signaling), CHAF1A (#5480s, Cell Signaling), mTOR (#2972s, Cell Signaling), phospho-mTOR (pSer2448) (#5536s, Cell Signaling), AKT (#9272S, Cell Signaling), phospho-AKT (pSer473) (#9271S, Cell Signaling), PRAS40 (#2691S, Cell Signaling), phospho-PRAS40 (pThr246) (#13175S, Cell Signaling), S6 (#2217S, Cell Signaling), phospho-S6 (pSer235/236) (#4858S, Cell Signaling), phospho-H2AX (pSer139)(#29380–1-ap, Proteintech) PARP2 (#39743, Active Motif), Cleaved Caspase-3 (Asp175) (#9661, Cell Signaling) and actin (#A5441, Sigma). Secondary antibodies were horseradish peroxidase–conjugated α-rabbit or α-mouse (GE Healthcare). Crystal violet cell viability assay Cells were plated in a 6-well plate at 3,000 cells/well and treated with the appropriate drugs for a total of 10 days, as previously described [20,34]. Cells were fixed with methanol and stained with 0.1% crystal violet solution before imaging using a tabletop scanner. Crystal violet was quantified using methanol extraction and analyzed at 540 nm on a M5 Spectramax plate reader (Molecular Devices). Data were normalized to vehicle-treated wells and fit to a sigmoidal dose-response curve using GraphPad Prism 10 software (GraphPad Software Inc). Drug combination effects were assessed by the Bliss independence model [35].If the combined effect was greater than expected for each drug additively, the response was classified as synergistic (Bliss score >0), while antagonism is concluded when the combination produces less than the expected additive effect (Bliss score <0). RNA interference Small interfering RNAs (siRNAs) targeting MSH6 and CHAF1A, as well as a negative control, were used for gene silencing experiments. The following siRNAs were obtained from Thermo Fisher Scientific: Silencer® Negative Control #1 siRNA (Catalog #AM4611), siMSH6–1 (Silencer™ Pre-Designed siRNA, Assay ID: 144497), siMSH6–2 (Silencer™ Pre-Designed siRNA, Assay ID: 144498), siCHAF1A (Silencer™ Pre-Designed siRNA, Assay ID: 16462). Transfections were performed in 6-well plates according to the manufacturer’s instructions. Knockdown efficiency was assessed by western blotting. Cells were seeded at a density of 3 × 10⁵ cells per well and treated with siRNAs and/or drugs for the indicated time. Following treatment, cells were harvested by trypsinization, washed, and resuspended in 1 mL of RPMI-1640 culture medium. A 20 µL aliquot of each cell suspension was transferred in triplicate into Corning black, flat-bottom 96-well plates. Cell viability was assessed using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Remaining cells were collected for immunoblot analysis. CRISPR-Cas9-mediated MSH6 knockout Oligonucleotides targeting the MSH6 gene were designed using the Benchling CRISPR Genome Engineering tool (https://www.benchling.com) and cloned into the lentiCRISPR v2 vector (Addgene #52961) [36] via the BsmBI restriction site. The resulting plasmids were transformed into Stbl2 competent cells for amplification. Single bacterial clones were selected and verified by Sanger sequencing using the hU6 forward and EF1α reverse primers. Two guide RNA sequences were used for MSH6 targeting: MSH6−1: Forward: 5′-CACCGGAACATTCATCCGCGAGAA-3′; Reverse: 5′-AAACTTCTCGCGGATGAATGTTCC-3′. MSH6−2: Forward: 5′-CACCGCAGGGACGTAACAACCCATC-3′; Reverse: 5′-AAACGATGGGTTGTTACGTCCCTGC-3′. Lentiviral particles were produced in HEK293T cells using the third-generation lentiviral packaging system (Applied Biological Materials, Cat# LV053). Viral supernatants were harvested and filtered to remove cellular debris. Target cells were transduced with 1 mL of viral filtrate supplemented with 4 µg/mL polybrene. After 24 hours, transduced cells were selected using puromycin. Single-cell clones were isolated by limiting dilution in 96-well plates and sequentially expanded into 6-well plates and 10 cm dishes. Successful MSH6 knockout was confirmed by western blot analysis. A non-targeting control vector (lentiCRISPR v2-sgControl; Addgene #125836) was used as a negative control. Chemical proteomics We have previously described the synthesis and validation of c-rucaparib [37]. Immobilization and drug pull-down experiments were performed as previously described in a step-by-step protocol [20,38] with modifications as follows: c-rucaparib were immobilized on NHS-activated Sepharose beads by overnight RT incubation in the presence of triethylamine. Successful coupling was confirmed using HPLC-MS and beads were blocked overnight with ethanolamine. Lysates (5 mg per sample) were preincubated with competition compound rucaparib (20 μM) or DMSO for 30 min at 4 °C. The drug beads were washed with DMSO followed by lysis buffer and affinity pull-down experiments were performed by incubating drug beads with lysates for 2 h at 4 °C. Beads were further washed on Bio-spin disposable chromatography columns (Bio-Rad) with lysis buffer, bound proteins were eluted by heating to 95 °C in 30 μl of Laemmli buffer for 5 min. A portion of each eluate was set aside for analysis by Western blotting. The eluates were run on SDS-PAGE, followed by in-gel trypsin digestion, and a nanoflow ultra high performance liquid chromatograph and nanoelectrospray orbitrap mass spectrometer (EvoSep and Q-Exactive plus) were used for LC-MS/MS. The sample was loaded onto a EvoTip pure (EV2013). Trapped peptides were eluted onto the analytical column (EV1106, 15 cm length x 150 µm ID, 1.9 µm particle size). A factory default extended gradient (88-minute) was used with solvent A (water + 0.1% formic acid) and solvent B (acetonitrile + 0.1% formic acid). Spray voltage was 1900 V. Capillary temperature was 275 °C. S lens RF level was set at 50. Data-dependent acquisition was performed using Top 16 precursors. The resolution for MS and MS/MS were set at 70,000 and 17,500 respectively. Dynamic exclusion was 15 seconds for previously sampled peaks. MaxQuant [39] (version 1.6.1.14) was used to identify human proteins using the UniProt database (May 2022) and quantify their relative intensities. Up to 2 missed trypsin cleavages were allowed. The mass tolerance was 20 ppm for the first search and 4.5 ppm for the main search. Carbamidomethyl cysteine was set as fixed modification. Methionine oxidation was set as a variable modification. Both peptide spectral match (PSM) and protein false discovery rate (FDR) were set at 0.01. The “match between runs” feature was activated to carry identifications across samples. Similar setting were used for Mascot (Matrix Science) to support data upload to PRIDE/ProteomeXchange [40]. The data were filtered for common contaminants, reverse hits, and intensity value = 0. Missing values were imputed with the lowest value of each column and iBAQ intensities were Log2 transformed. A cutoff of 1 for Log2 ratios of pull downs and competition controls, and p value (<0.05) were applied. The experiment was performed with three biological replicates. Chemical proteomics was performed on six cell lines (three drug-sensitive and three drug-resistant). SKOV3 cells were excluded from further analysis due to inconsistent target enrichment of PARP1. ADP-ribosylation proteomics These experiments were performed as previously described [20,33]. Briefly, the cells were treated with 10 μM rucaparib or DMSO for 1 h, medium was removed, and the cells were treated with 0.5 mM 6YnAd and 0.5 mM 2YnAd for an additional hour. Whole cell lysates were prepared, and total protein was quantified for each sample using the Bradford assay. For each condition, 500 μg of total protein was subjected to click reactions using Azide-PEG3-Biotin or Azide-TAMRA-Biotin capture reagent. Proteins were precipitated using methanol/chloroform/water and air-dried precipitates were resuspended. An aliquot of protein (30 μg) was loaded per gel lane (4%–15% mini-PROTEAN TGX precast gels, Bio-Rad) and resolved by SDS-PAGE. The gels were scanned for fluorescence labeling and read on an Odyssey FC Imager using Image studio software (Licor). 500 μg of protein was subjected to affinity enrichment on NeutrAvidin-agarose beads (Thermo Scientific, Cat# 29200). After extensive washing, the beads were subjected to 3 mM DTT treatment, 10 mM iodoacetamide treatment, and overnight trypsinization. Samples were acidified to pH 3 using formic acid, allowed to stand for 5 min, centrifuged, and the supernatant was collected. Beads were washed with 0.1% formic acid in water, centrifuged, and supernatants were mixed with the previous supernatants. Samples were labeled using TMT reagents as described by the manufacturer (Thermo Fisher TMT 18plex Isobaric Mass Tagging Kit, # A58335). Labeling efficiency was confirmed by LC-MS/MS. Each batch included a pooled DMSO-treated sample from all six cell lines as an internal control for batch normalization. After sample combination and lyophilization, peptides were redissolved in 250 μl of aqueous 20 mM ammonium formate buffer (pH 10.0). Basic pH reversed-phase liquid chromatography separation was performed on an XBridge column (Waters). The concatenated peptide fractions were dried by vacuum centrifugation. A nanoflow ultra high performance liquid chromatograph (RSLC, Thermo) and an electrospray bench top orbitrap mass spectrometer with high field asymmetric waveform ion mobility spectrometry (Orbitrap Exploris 480 with FAIMS, Thermo) were used for tandem mass spectrometry peptide sequencing experiments. The sample was first loaded onto a pre-column (C18 PepMap100, 2 cm x 100 µm ID packed with C18 reversed-phase resin, 5 µm particle size, 100 Å pore size) and washed for 8 minutes with aqueous 2% acetonitrile and 0.04% trifluoroacetic acid. The trapped peptides were eluted onto the analytical column (C18 PepMap100, 75 µm ID x 25 cm, 2 µm particle size, 100 Å pore size, Thermo). The 120-minute gradient was programmed as: 95% solvent A (aqueous 2% acetonitrile + 0.1% formic acid) for 8 minutes, solvent B (aqueous 90% acetonitrile + 0.1% formic acid) from 5% to 38.5% in 90 minutes, then solvent B from 50% to 90% B in 7 minutes and held at 90% for 5 minutes, followed by solvent B from 90% to 5% in 1 minute and re-equilibration for 10 minutes. The flow rate on analytical column was 300 nl/min. Spray voltage was 2100 V, and capillary temperature was 300 °C. Cycle time was set at 1.5 sec for data dependent acquisition for two FAIMS compensation voltage values (−45 and −65). The resolution for MS and MS/MS scans were set at 120,000 and 45,000 respectively. Dynamic exclusion was 15 seconds for previously sampled peptide peaks. MaxQuant (version 1.6.14.0) [39] was used to identify peptides and quantify the TMT reporter ion intensities. Protein database was downloaded from UniProt in March 2023. Up to 2 missed trypsin cleavages were allowed per peptide. Carbamidomethyl cysteine was set as a fixed modification, and methionine oxidation was set as a variable modification. Both peptide spectral match (PSM) and protein false discovery rate (FDR) were set at 0.01. The “match between runs” feature was activated. The data were then filtered for common contaminants (e.g., non-human proteins, etc.) and reverse sequences. For the analysis and comparison of TMT 18-plex data, the reporter ion intensity was used for the relative quantification of each peptide. IRON (iterative rank-order normalization) of MaxQuant data was performed as described before [41]. The proteins with were filtered by three different criteria: Criterion 1 (C1): Proteins with an average log2 ratio (sensitive vs. resistant cells, DMSO-treated) ≥ 2 standard deviations (SD) and p ≤ 0.05. Criterion 2 (C2): Proteins with a log2 ratio of rucaparib vs. DMSO < 0 and p < 0.05 in individual cell lines. Criterion 3 (C3): Proteins showing a log2 ratio of rucaparib vs. DMSO < 0 in at least two PARPi-sensitive cell lines. The experiment was performed with three biological replicates. Each treated sample was run as two technical replicates. Pull-down of substrate proteins of PARP1 using adenosine probes Cells were treated with or without rucaparib for 1h, followed by treatment with 0.5 mM mixture of the probes. Control experiments were done without probe. Click chemistry was carried out using Azide-TAMRA-Biotin as described before [20,33]. Following protein precipitation, 30 μg of protein was set aside as input control. A total of 500 μg of protein was subjected to affinity enrichment using NeutrAvidin-Agarose beads. The beads were washed once, the beads and input were boiled at 95°C for 5 minutes in 2X loading buffer (Bio-Rad) containing 10% β-mercaptoethanol and proteins were collected by centrifugation. The proteins were resolved by SDS-PAGE on 4%–15% precast gels and scanned for fluorescence labeling using Licor. The input gel was stained with AcquaStain (Bulldog Bio). The gel with enriched proteins was transferred to a nitrocellulose membrane for Western blotting with an anti-CHAF1A antibody. Quantification and statistical analysis Data was obtained from at least three independent experiments and shown as the mean ± SD. Data was analyzed using Microsoft Excel and GraphPad Prism 10.0. Statistical analyses were performed using Student’s t test (paired or unpaired, as appropriate) and synergy was determined by the Bliss independence model [35]. P value of <0.05 was considered statistically significant. All statistical details are included in the figure legends. All MaxQuant data were first filtered for peptides with PEP score < 0.05. Furthermore, reverse and contaminant peptides and peptides with no intensity were excluded. Data were then normalized using IRON [41]. Gene set enrichment analyses and data visualization The heatmap of enriched terms across the input of gene lists from chemical proteomics was created by Metascape [42] and colored according to p-values. Protein–protein interaction analysis was carried out with all protein interaction databases using the Metascape [42] and STRING [43]. Results BRCA-proficient ovarian cancer cells show a wide range of sensitivity to PARP inhibitors To evaluate the sensitivity of BRCA-proficient OC cells to PARPis, we treated 12 BRCA-proficient OC cell lines, and one immortalized fallopian tube epithelial (iFTE) cell line expressing mutant p53 [32], with the FDA approved PARPis olaparib, rucaparib and niraparib for 10 days. Clonogenic viability assays revealed that the response to PARPi treatment varied greatly across cell lines, indicating differential sensitivity profiles (Fig 1A). Based on their IC50 values, relative to rucaparib’s maximal plasma concentration (1.94 μM), and consistency across the other PARPis olaparib and niraparib, cell lines were classified as sensitive or resistant (Fig 1B). DOV13 cells exhibited resistance to rucaparib and niraparib, but remained relatively sensitive to olaparib. Considering that rucaparib was FDA-approved as maintenance therapy for recurrent OC regardless of BRCA mutation status, we focused our analysis primarily on this PARPi. Notably, at its clinically relevant peak plasma concentration (Cmax = 1.94 μM) [44], only about a third of the tested cell lines exhibited greater than 50% reduction in viability, suggesting that the majority of cell lines were resistant. For subsequent studies, we therefore selected A2780, OVCAR8, and Caov3 as BRCA-proficient ovarian cancer cell lines representative for PARPi-sensitivity (Fig 1B). OVCAR3 was excluded despite its sensitivity due to previously reported deep BRCA2 deletions, although its mRNA expression levels were comparable to those of other OC cell [45]. HEYA8, SKOV3, and OVCA432 were selected as representative BRCA-proficient ovarian cancer PARPi-resistant lines. PARPi sensitivity of BRCA-proficient OC cell lines. (A) Crystal violet clonogenic survival assay for a panel of BRCA-proficient ovarian cancer cell lines treated with olaparib, rucaparib, or niraparib at concentrations of 0, 0.08, 0.4, 2, 10, 50 μM after treatment for 10 days. Upper panel: quantification of crystal violet intensity; lower panel: representative images of stained wells. Error bars represent the mean ± SD of three biological replicates. (B) Half-maximal inhibitory concentration (IC₅₀) values derived from the dose–response curves shown in panel A, summarizing the relative sensitivity of each cell line to olaparib, rucaparib, and niraparib. The heatmap at the bottom indicates relative PARPi sensitivity based on IC₅₀ values relative to rucaparib Cmax (1.94 μM). Light peach indicates IC₅₀ < Cmax and light blue indicates IC₅₀ > Cmax. Representative PARPi-sensitive and -resistant cell lines were selected based on consistently low or high IC₅₀ rankings across all three PARP inhibitors. PARP1 forms differential protein complexes with PARP2 and MSH6 in PARPi-sensitive and -resistant OC cells We previously have reported a chemical proteomics-based affinity purification approach with various clinical PARPis [20,37,46], and furthermore observed differential protein binding partners of PARP1 in BRCA1-deficient and BRCA1-proficient isogenic OC cell lines [20]. To explore the differential composition of PARP1-based protein complexes between PARPi-sensitive and PARPi-resistant BRCA-proficient OC cells, we employed a mass spectrometry (MS)-based chemical proteomics approach using rucaparib as a PARP1 probe (Fig 2A). Chemical proteomics with rucaparib in PARPi-sensitive and -resistant BRCA-proficient OC cell lines. (A) Workflow of competitive chemical proteomics using rucaparib probe to identify PARP1 and associated interacting proteins in the most PARPi-sensitive and -resistant BRCA-proficient OC cell lines. Created in BioRender. Deng, O. (2026) https://BioRender.com/syisc8s. (B) Circos plot (upper panel) of the overlap of enriched interactors identified by rucaparib pulldown compared to competition control across five cell lines. The potential interaction partners were defined by log2 fold change ≥1 and p ≤ 0.05 The heatmap (lower panel) displays differentially enriched ontology clusters by analysis of the potential rucaparib targets across cell lines using Metascape [42] (minimum overlap = 3, p-value ≤ 0.01, minimum enrichment = 1.5). Gray boxes indicate lack of statistical significance. (C) Protein-protein interaction network and differential composition of the PARP1 complex in PARPi-resistant (blue) versus -sensitive (red) cell lines. Protein interaction network was generated using Metascape with input genes selected via STRING [43] (minimum interaction score cutoff = 0.4). Color code for pie sector represents a protein list from different cell lines. Venn diagrams show the number of overlapping potential PARP1 interactors among PARPi-sensitive (lower right) and -resistant (upper right) cell lines. (D) Immunoblot of pulldowns using c-rucaparib affinity beads incubated with lysates from Caov3, A2780, OVCA432, and HEYA8 cells without (PD) or with 20 μM free rucaparib competition (CT). Representative blots from three independent experiments are shown. TCL: total cell lysate. Blots for PARP1 and MSH6 were obtained from the same gel. For MSH6, lower (LE) and higher (HE) exposure images are shown. (E) Western blot analysis of eluates from immunoprecipitation (IP) with MSH6 or PARP1 antibodies. A2780 and HEYA8 cells were treated with 10 μM rucaparib for 1 hour and subjected to co-IP, followed by Western blotting with the indicated antibodies. Input samples were run alongside each co-IP (MSH6 and PARP1) in separate gels. We harnessed a previously described rucaparib analogue [37] as affinity bait for chemical proteomics experiments with three different PARPi-sensitive (A2780, Caov3, OVCAR8) and -resistant (SKOV3, OVCA432, HEYA8) OC cell lines. Notably, although this information was not available for OVCA432, cell lines A2780, OVCAR8, Caov3, HEYA8 and SKOV3 have been shown previously to be HR proficient [21–24]. Prior to MS analysis, we confirmed PARP1 enrichment by western blotting (WB) using the rucaparib affinity matrix across three biological replicates. As expected, PARP1 was consistently enriched in all cell lines and was fully competed by free rucaparib, regardless of their PARPi sensitivity (S1A Fig in S1 File). Label-free quantitative LC-MS/MS analysis and subsequent data filtering by comparison with negative control/competition samples derived from rucaparib affinity purifications in the presence of unmodified rucaparib, identified binding of specific drug targets and their interaction partners (Fig 2A and S1 Table). Among the six cell lines analyzed, SKOV3 was excluded due to an anomalously lower PARP1 enrichment in the drug pull-down condition compared to the competition condition. Importantly, 13 proteins were shared among all three PARPi-sensitive cell lines, whereas 10 proteins were commonly observed across both resistant cell lines (HEYA8 and OVCA432) (S1 Table). Pathway analysis of the potential targets using Metascape [42] revealed enrichment of the cell cycle, protein-RNA complex organization, chromosome organization, regulation of translation and DNA metabolic process across all cell lines (Fig 2B). However, DNA metabolic processes were significantly more enriched in PARPi-sensitive cells compared to resistant ones. In addition, PARP1 protein interaction subnetwork analysis by STRING [43] identified PARP1/CTNND1 complexes to be predominantly enriched in PARPi-resistant cells (Fig 2C). Conversely, the known PARP1 binding partners PARP2 (which is furthermore a direct rucaparib target) and the key mismatch repair protein MSH6 were consistently enriched in PARPi-sensitive cells, but not in resistant cells. Interestingly, PARP3 was enriched in all the PARPi-sensitive cells, but also in the PARPi-resistant HEYA8 cells. Notably, immunoblotting of PARP1-associated interactors further confirmed a co-enrichment of MSH6 in rucaparib pulldowns. Comparison with each own rucaparib competition control, which is critical for distinguishing specific interactions from background, moreover indicated that this interaction was specific in the PARPi-sensitive Caov3 and A2780 cells, but not in the PARPi-resistant OVCAR432 and HEYA8 cells where MSH6 was not competed (Fig 2D). Furthermore, co-immunoprecipitation (co-IP) experiments revealed that the PARP1/MSH6 and PARP1/PARP2 complexes were more abundant in A2780 cells compared to HEYA8 cells (Fig 2E, S1B Fig in S1 File). Rucaparib treatment slightly enhanced PARP1/MSH6 complex formation in A2780 cells but reduced it in HEYA8 cells, suggesting that PARP1/MSH6 interaction is more pronounced in PARPi-sensitive OC cells. Whereas PARP2 was co-immunoprecipitated by PARP1 in both cell lines, this was also observed upon MSH6 co-IP suggesting a shared protein complex of these three proteins. In contrast to MSH6, however, rucaparib treatment reduced the amount of co-immunoprecipitated PARP2 similarly in both cell lines. Taken together, chemical proteomics with rucaparib revealed that PARP1/PARP2/MSH6 complexes are preferentially enriched in PARPi-sensitive ovarian cancer cells. These findings highlight distinct PARP1-associated protein networks that may contribute to differential PARPi sensitivity in ovarian cancer. CHAF1A is ADP-ribosylated and preferentially interacts with PARP1 and MSH6 in PARPi-sensitive OC cells Considering that some of the observed PARP1 interactions were modulated by treatment with the PARPi, rucaparib, it was possible that these interactions were governed by PARylation. To identify differential ADP-ribosylation patterns and associated signaling events in response to rucaparib treatment between PARPi-sensitive and -insensitive cells, we performed ADP-ribosylation proteomics using a previously described metabolic labeling strategy with 6-alkyne (6Yn)- and 2-alkyne (2Yn)-adenosines probes, which in situ are incorporated in ADP ribose [20,33]. Cells were treated with rucaparib or DMSO followed by 6/2Yn-adenosine probes. Copper-catalyzed click chemistry labeled proteins with biotin which enabled enrichment using NeutrAvidin-agarose beads (Fig 3A). In-gel fluorescence imaging confirmed significant enrichment of ADP-ribosylated proteins in the probe-labeled samples, which was markedly reduced by rucaparib treatment (S2A Fig). Quantitative proteomics was performed using tandem mass tags (TMT) and quantified by LC-MS/MS. Following data filtering and normalization, 1856 proteins were quantified in this TMT experiment (S2 Table). Comparative statistical analysis between PARPi-sensitive and -resistant cells (under DMSO conditions) revealed 46 and 36 proteins preferentially ADP-ribosylated in sensitive and resistant cells, respectively, which had an average log2 ratio (sensitive vs. resistant) ≥ 2 standard deviations and p ≤ 0.05 (criterion C1) (Fig 3B). Further data filtering by criteria C2 (log2 ratio of rucaparib vs. DMSO < 0 and p < 0.05) and C3 (log2 ratio of rucaparib vs. DMSO < 0 in at least two PARPi-sensitive cell lines) highlighted four proteins in sensitive cells and five in resistant cells that exhibited reduced signals in ADP-ribosylation upon rucaparib treatment. Specifically, these targets were CHAF1A, LSM12, RPP30 and FHOD1 in PARPi-sensitive cells, and LMNA, DENR, ANXA2, ANXA5 and RAP1A in -resistant cells (Fig 3B and Fig S2B in S1 File). Proteome-wide identification of ADP-ribosylation profile and signaling in response to rucaparib in BRCA-proficient OC cells. (A) Schematic of the experimental workflow for identification of ADP-ribosylated proteins. Created in BioRender. Deng, O. (2026) https://BioRender.com/syisc8s. Indicated PARPi-sensitive and -resistant cell lines were treated with or without rucaparib (10 μM) for 1 hour followed by labeling with a mixture of 6-alkyne adenosine and 2-alkyne adenosine probes (0.5 mM each) for 1 hour. CuAAC: copper(I)-catalyzed azide-alkyne cycloaddition. (B) Upper panel: funnel diagrams of the prioritization workflow based on the three selection criteria. Lower panel: volcano plots of the differential enrichment of ADP-ribosylated endogenous proteins between PARPi-sensitive and -resistant cell lines in DMSO-treated samples. Proteins meeting selection threshold C1 are highlighted in pink (enriched in sensitive cells) or blue (enriched in resistant cells). Proteins that also meet criteria C2 and C3, representing consistent inhibition by rucaparib in at least two sensitive or resistant cell lines, are labeled and indicated by larger dot sizes. Detailed criteria are described in the Methods. (C) Integrated analysis of selected significantly modulated proteins identified by chemical proteomics and ADP-ribosylation proteomics in PARPi-sensitive (left panel, red) and -resistant cells (right panel, blue). Proteins identified through ADP-ribosylation proteomics are marked with black circles. Proteins were mapped to STRING enrichment with uniport keyword categorization [43], a false discovery rate (FDR) ≤ 0.05 and minimum interaction confidence score of 0.4. (D) Upper panel: Western blot analysis for CHAF1A of enriched ADP-ribosylation eluates from PARPi-sensitive A2780 and PARPi-resistant HEYA8 cells, with quantification of CHAF1A shown in the lower right, error bars represent mean ± SD of three biological replicates. Cells were treated with or without rucaparib, followed by probe labeling. Lower panel: qualitative assessment of probe labeling in both cell lines after enrichment by total input protein profile stained with Coomassie Blue prior to enrichment (left) and in-gel fluorescence scanning after the enrichment (middle). To explore functional relevance, we performed protein-protein interaction enrichment analysis using STRING [43] by integrating ADP-ribosylation proteomics and PARP1 interactors from chemical proteomics. This analysis revealed CHAF1A, MSH6, PARP1 and PARP2 complexes and a preferential enrichment for DNA repair in PARPi-sensitive cells. In contrast, enrichment in resistant cells indicated CTNND1, RAP1A, ANXA5, ANXA2 and PARP1 complexes, which involved annexin, calcium/phospholipid-binding, isopeptide bond, Ubl conjugation and acetylation pathways (Fig 3C). Although MSH6 was not one of the proteins detected by PARylation proteomics, MSH6 has been reported to interact with CHAF1A (also known as CAF-1 p150) [47], a subunit of the chromatin assembly factor 1 complex, which was found to be ADP-ribosylated in sensitive cells (Fig 3B). Subsequent immunoblot analysis of ADP-ribosylation pulldowns confirmed ADP-ribosylation of CHAF1A in both A2780 and HEYA8 cells as it was enriched in the probe-labeled samples compared to unlabeled controls and reduced upon treatment with the PARPi rucaparib (Fig 3D). Consistent with the MS-based analysis, CHAF1A was furthermore preferentially ADP-ribosylated in A2780 cells compared to HEYA8 cells. PARP1 facilitates repair by PARylating target proteins, thereby leading to chromatin relaxation and recruitment of DNA repair factors [48–50]. This premise led us to test if CHAF1A and PARP1/MSH6 form complexes. Co-IP of MSH6 revealed that MSH6 interacted with both PARP1 and CHAF1A and that rucaparib treatment further enhanced the PARP1/MSH6/CHAF1A complexes in A2780 cells, but reduced their enrichment in HEYA8 cells (Fig S2C in S1 File), suggesting that PARP1/MSH6/CHAF1A interactions are more pronounced in PARPi-sensitive OC cells, particularly in response to rucaparib treatment. This result furthermore indicated that, whereas CHAF1A was indeed PARylated, the interaction of PARP1, MSH6 and CHAF1A in A2780 cells itself was not dependent of PARylation. In summary, these data show different global ADP-ribosylation landscapes between PARPi-sensitive and -insensitive OC cells and suggest that PARylation of CHAF1A, which participates in the PARP1/MSH6 complex, is downregulated by rucaparib specifically in PARPi-sensitive OC cells. MSH6 expression correlates with drug sensitivity We observed that the PARP1/MSH6/CHAF1A complex is preferentially formed in PARPi-sensitive BRCA-proficient OC cells. To investigate the functional role of PARP1, MSH6 and CHAF1A in modulating the PARPi sensitivity of OC cells, we next assessed their protein expression levels using the LinkedOmicsKB web portal [44]. Analysis of Clinical Proteomic Tumor Analysis Consortium (CPTAC) proteomic data revealed that both MSH6 and PARP1 protein levels were significantly upregulated in ovarian tumor tissues compared to normal ovarian tissues (Fig 4A). In contrast, CHAF1A did not show significant differential expression. Interestingly, PARP2 expression was relatively low compared to other cancer types and showed no significant difference between normal tissues and ovarian cancer (Fig S3A in S1 File). We next examined whether expression of these proteins was correlated in ovarian tumors. This analysis indicated that PARP1 protein abundance was significantly positively correlated with MSH6 expression (Fig 4B). However, with CHAF1A, PARP1 only showed a weak correlation, and no correlation was observed between MSH6 and CHAF1A protein expression. Relationship between MSH6/PARP1/CHAF1A expression and overall survival. (A) Protein expression analysis of PARP1, MSH6, and CHAF1A using CPTAC data accessed through the LinkedOmicsKB web portal [44], comparing primary ovarian tumors and normal ovarian tissues. (B) Protein expression correlation analysis among MSH6, PARP1, and CHAF1A in OC. Scatter plots and correlation between PARP1 and MSH6 (left panel), PARP1 and CHAF1A (middle panel), and MSH6 and CHAF1A (right panel). SCC: Spearman correlation coefficient. (C) Prognostic role of gene expression of MSH6 in OC patients. Kaplan–Meier plot [51] showing MSH6 (left panel) is not associated with OS in OC; however MSH6 expression is associated with OS in the chemotherapy with taxol treatment groups (right panel). (D) Western blot analysis of protein expression levels in BRCA-proficient OC cell lines. Quantified protein levels for MSH6 and PARP1 are presented on the right, with each dot representing the mean of three biological replicates per cell line. Erro bars indicate the mean ± SD for each group (sensitive, intermediate and resistant). Protein expression values were normalized to those of the A2780. The lower left panel displays the correlation analysis between MSH6 and PARP1 expression across OC cell lines. To evaluate the prognostic significance of MSH6 and PARP1 in OC, we next performed a survival analysis using online Kaplan-Meier plotter [51], which indicated that MSH6, PARP1 and CHAF1A gene expression levels were not significantly associated with overall survival (OS) in ovarian cancer patients (Fig 4C left panel, Fig S3B in S1 File). However, stratified analysis revealed that in patients receiving chemotherapy regimens, including taxol (Fig 4C right panel), platinum (Fig S3C left panel in S1 File), taxol + platinum (Fig S3C right panel in S1 File), elevated MSH6 expression was significantly associated with better OS. These results suggest that MSH6 expression may be predictive of chemotherapy response. Additionally, Western blot analysis of a panel of BRCA-proficient OC cells demonstrated that the protein expression levels of PARP1, MSH6, and PARP2 were markedly higher in PARPi-sensitive ovarian cancer cell lines, particularly OVCAR3, A2780, Caov3, and OVCAR8, compared to less sensitive lines (Fig 4D). In contrast, CHAF1A expression did not correlate with the expression of MSH6 protein or PARPi sensitivity (Fig S3D in S1 File). These results highlight both, PARP1 and MSH6, as potential biomarker candidates for drug response in ovarian cancer, particularly in the context of PARP inhibitor sensitivity and chemotherapy-based treatment regimens. MSH6 silencing leads to PARP inhibitor resistance To investigate the functional role of MSH6 in OC cells, we next assessed its impact on PARPi response in PARPi-sensitive and -resistant BRCA-proficient OC cells. Genetic silencing of MSH6 using two independent siRNAs had no significant effect on cell survival alone, but significantly rescued cell viability in response to rucaparib treatment (Fig 5A). Although this effect was to some extent observed also in PARPi-resistant HEYA8 cells, it was markedly more pronounced in A2780 and Caov3 cells as these cell lines were much more sensitive to PARPi treatment to begin with. Consistently, CRISPR-Cas9-based gene knockout of MSH6 strongly rescued A2780 cells from rucaparib treatment and only marginally affected PARPi response of HEYA8 cells (Fig 5B). These results suggested that MSH6 promotes PARPi sensitivity in BRCA-proficient OC cells and that low protein levels or loss of MSH6 causes PARPi resistance. Effect of MSH6 on cell viability. (A, B) Effects of MSH6 targeting by siRNA-based gene silencing (A) in PARPi-sensitive A2780 cells, Caov3 cells and PARPi-resistant HEYA8 cells, or by CRISPR-based gene knockout (B) in A2780 cells and HEYA8 cells, with or without 10 μM rucaparib treatment for 5 days. Cell viability was measured by CellTiter-Glo (CTG viability) assays. NT: non-targeting control. Loss of MSH6 induces mTOR survival signaling To explore the underlying mechanism of how MSH6 is promoting PARPi sensitivity, we next queried PARP1 and MSH6 protein expression and determined their associations with pathways using LinkedOmicsKB [44]. This analysis revealed that the protein abundance of both PARP1 and MSH6 were strongly anti-correlated with the KINASE-PSP_Akt1/AKT1 pathway in ovarian tumor samples (Fig S4A and B in S1 File). In addition, this identified AKT1S1 (aka PRAS40) T246, a canonical substrate of AKT1 critical for downstream regulation of mTOR when part of the mTORC1 complex [52,53], as the top associated phosphosite suggesting a link between MSH6 and mTOR signaling (Fig S4C in S1 File). Therefore, we next examined the effects of MSH6 targeting and rucaparib treatment on the mTORC1 pathway. We knocked down the MSH6 gene by two different siRNA in PARPi-sensitive A2780 and PARPi-resistant HEYA8 cells and then treated the cells with vehicle or rucaparib (10 μM for 36 hrs). In A2780 cells, rucaparib treatment alone led to reduced levels of mTOR, p-mTOR (Ser2448), and downstream phosphorylation of p-S6 (Ser235/236) (Fig 6A, S4D and S4E in S1 File). In contrast, HEYA8 cells displayed increased levels of these signaling components following rucaparib exposure, suggesting that mTORC1 pathway activation may contribute to intrinsic resistance to PARPi. Notably, MSH6 knockdown enhanced phosphorylation of p-mTOR (Ser2448), as well as the expression and phosphorylation of PRAS40 upstream of mTORC1 in both cell lines. An increase in p-AKT (Ser473) levels was also observed in rucaparib-treated HEYA8 cells upon MSH6 depletion, whereas this effect was not observed in A2780 cells. These findings suggest that loss of MSH6 promotes compensatory activation of mTOR-dependent survival signaling, providing a potential mechanism through which MSH6 depletion contributes to reduced PARPi sensitivity. Combination effects of co-targeting PARP1 and mTOR in OC cells. (A) Western blot analysis of A2780 (left) and HEYA8 (right) cells following MSH6 knockdown via siRNA and treatment with either DMSO or 10 μM rucaparib for 36 hours, with quantification shown on the bottom. (B) Upper panel: Effects of CHAF1A targeting by siRNA silencing for 3 days on cell viability of A2780 and HEYA8 cells as assessed by CTG assay. Lower panel: Western blot analysis of the effects of CHAF1A knockdown by siRNA on cleavage of PARP1 and caspase 3, on γH2AX, and on mTOR signaling. (C) Clonogenic survival assays of A2780 and HEYA8 cells treated with rucaparib (3 μM) alone or in combination with 0.5 μM mTOR inhibitors (rapamycin, everolimus) or the S6 kinase inhibitor LY2584702 for 7 days as determined by crystal violet staining. (D) Quantification of crystal violet staining intensity from C (left panel), and synergy as determined using ΔBliss (right panel). Positive ΔBliss values indicate synergy, negative ΔBliss values antagonism. Error bars represent mean ± SD of three biological replicates. Ruca: Rucaparib; Rapa: rapamycin; Eve: everolimus; LY: LY2584702. Interestingly, MSH6 knockdown also increased total CHAF1A expression in both cell lines, independent of rucaparib treatment. Consistently, silencing of CHAF1A significantly inhibited cell survival, which was especially pronounced in the PARPi-sensitive A2780 cells (Fig 6B). CHAF1A knockdown also strongly induced apoptosis and DNA damage as evidenced by cleavage of caspase 3 and PARP1, and phosphorylation of H2AX, respectively, in the PARPi-sensitive A2780 cells, whereas this effect was barely discernible in the PARPi-resistant HEYA8 cells (Fig 6B). CHAF1A knockdown furthermore attenuated mTOR signaling, primarily by reducing mTOR protein levels, suggesting that CHAF1A acts downstream of MSH6 to regulate the mTOR signaling axis. Finally, we tested whether mTOR pathway inhibition enhances PARPi efficacy. Combination of rucaparib with either of the two mTORC1 inhibitors rapamycin or everolimus showed greater synergy in HEYA8 compared to A2780 compared to single agent rucaparib, as A2780 cells were much more sensitive to rucaparib to begin with (Fig 6C and D). Consistently, whereas the S6 kinase inhibitor LY2584702 alone had minimal effects, when combined with rucaparib it led to enhanced efficacy in HEYA8 cells. Together, these findings identify a role for MSH6 in promoting PARPi sensitivity through CHAF1A-mediated regulation of mTORC1 signaling and highlight mTOR activation as a key mechanism of intrinsic PARPi resistance in BRCA-proficient ovarian cancer. Discussion Overall, our findings support a model in which PARPi-sensitive and PARPi-resistant BRCA-proficient OC cells exhibit distinct PARP1-associated protein complexes and downstream signaling. PARPi-sensitive compared to PARPi-resistant cells preferentially featured a PARP1-MSH6-CHAF1A complex and higher CHAF1A ADP-ribosylation, reduced by PARPi treatment, which prevented cells to launch PARPi-adaptive mTOR survival signaling. In contrast, PARPi-resistant cells showed compensatory activation of mTOR signaling following PARPi treatment and enhancement of rucaparib effects by pharmacological inhibition of the mTOR pathway. These findings suggest that compensatory mTOR signaling contributes to PARPi resistance and that mTOR pathway inhibition may be a potential combination strategy for PARPi-resistant cells. PARPis have shown significant clinical benefit in BRCA-mutant OC. However, their efficacy in BRCA-proficient ovarian tumors remains variable and underexplored. Our study demonstrates that among BRCA-proficient OC cell lines, PARPi sensitivity is heterogeneous and not strictly correlated with BRCA1/2 and TP53 mutation status, suggesting the involvement of alternative molecular mechanisms [54]. To further investigate the mechanisms underlying PARPi sensitivity and resistance, we employed chemical proteomics and ADP-ribosylation proteomics to examine PARP1 protein complexes and PARylation profiles in PARPi-sensitive and -resistant BRCA-proficient OC cells, including the endometrioid OC cell line A2780. Our proteomic analysis revealed a previously unrecognized PARP1/MSH6/CHAF1A complex enriched in PARPi-sensitive BRCA-proficient cells. Although PARP1 and MSH6 have been previously reported to interact during mismatch repair (MMR) [55,56], particularly during the recognition and signaling of DNA mismatches, our chemical proteomics data demonstrated selective enrichment of PARP1/MSH6 complexes in PARPi-sensitive cells with no apparent enrichment of MSH2. This finding suggests an unconventional, potentially MMR-independent role for MSH6 in modulating PARPi sensitivity. MSH6 has been extensively studied in the context of MMR deficiency and microsatellite instability (MSI) [57–60]. However, MSI-high tumors are relatively uncommon in ovarian cancer, occurring in approximately 1–3% of serous cases [61–65]. Although MSI status was not directly assessed in the present study, previous reports have classified SKOV3 as MSI-H, whereas the remaining cell lines used in this study are generally considered microsatellite stable (MSS) [66,67]. Therefore, the differential MSH6 expression and PARP1/MSH6 complex formation observed in our models are unlikely to be explained solely by classical MMR deficiency. Instead, these findings support the possibility that MSH6 may have additional functions beyond canonical mismatch repair, potentially through PARP1-associated signaling pathways that influence PARPi response. The relationship between MSH6-associated signaling, MSI phenotypes, and PARPi sensitivity warrants further investigation. Notably, rucaparib treatment enhanced the enrichment of the PARP1/MSH6/CHAF1A complex in sensitive cells, whereas this complex was dissociated in resistant cells. The interaction between CHAF1A and MSH6 has previously been shown to be phosphorylation-dependent in that only the dephosphorylated form binds MSH6 [47]. In our study, we determined ADP-ribosylation of CHAF1A, which was significantly enriched in PARPi-sensitive cells and reduced upon rucaparib treatment. These findings support a model in which PARP1 directly modifies CHAF1A via ADP-ribosylation, which may also affect phosphorylation, thereby regulating its interaction preferences and functional activity. These findings indicate that CHAF1A ADP-ribosylation is associated with PARPi response and may contribute to the differential assembly of the PARP1/MSH6/CHAF1A complex. However, whether CHAF1A is directly ADP-ribosylated by PARP1 or other known PARP family targets, such as PARP2 or tankyrase [37,68], ADP-ribosylation occurs at specific functional sites or contributes directly to CHAF1A’s regulatory activity requires further studies using PARP1 knockdown, site-directed mutagenesis and mapping of CHAF1A PARylation sites. CHAF1A is a chromatin assembly factor implicated in replication stress resolution and nucleosome assembly at sites of transcription-replication conflicts (TRCs), which are exacerbated by PARPi treatment [69–71]. In drug-sensitive cells, PARP1-mediated PARylation of CHAF1A was inhibited and may prevent its phosphorylation-dependent recruitment to PCNA [72], instead favoring association with MSH6 after rucaparib treatment. This sequestration may reduce CHAF1A’s role in chromatin reassembly and promote replication stress, contributing to PARPi sensitivity. However, the functional consequences of CHAF1A ADP-ribosylation, its impact on protein interactions and PARPi response were not examined in this study and will require further investigation. Importantly, we discovered a link between MSH6 and mTOR signaling. Integrative pathway analysis from CPTAC revealed a strong correlation between MSH6 expression and the AKT1/mTOR axis in ovarian tumors. Functionally, rucaparib treatment reduced mTOR signaling in MSH6-high sensitive cells, while MSH6 knockdown increased phosphorylation of mTORC1 signaling pathway components in both sensitive and resistant cells. MSH6 silencing also rescued PARPi-induced cell death, suggesting that loss of MSH6 promotes PARPi resistance via upregulation of mTOR signaling. Interestingly, CHAF1A levels were upregulated following MSH6 silencing and appeared to act downstream of MSH6 to sustain mTOR signaling. CHAF1A knockdown reduced mTOR signaling, induced apoptosis and increased DNA damage particularly in sensitive A2780 cells, indicating its critical role in mediating mTOR-driven resistance. These findings link MSH6, probably through modulation of CHAF1A–mTOR signaling, to PARPi resistance in BRCA-proficient OC. However, whether and how CHAF1A is directly regulated by MSH6 or serves as a critical mediator connecting MSH6 loss to mTOR activation remains to be determined. Consistently, we observed that combination with mTORC1 inhibitors (rapamycin or everolimus) or the S6 inhibitor LY2584702 synergized with rucaparib in HEYA8 cells, where mTOR signaling was induced by rucaparib. This highlights the therapeutic value of targeting downstream mTOR effectors to overcome intrinsic resistance. In conclusion, using an integrative proteomics approach, we identify a novel PARP1–MSH6 interaction that regulates PARPi sensitivity through modulation of CHAF1A-mTOR signaling in BRCA-proficient ovarian cancer cells. Our findings suggest that MSH6 impairs PARPi resistance through suppressing CHAF1A-mediated induction of mTOR signaling, and that MSH6 expression or the interaction of PARP1 with MSH6 may serve as potential predictive biomarker candidates for PARPi therapy and mTORC1 inhibitors. These insights support combination PARPi with mTOR inhibition as a promising strategy to overcome intrinsic resistance in BRCA-proficient OC. Furthermore, CHAF1A's dual roles in chromatin regulation and mTOR signaling position it as a potential therapeutic target to overcome PARPi resistance. Because this study is based on integrative proteomics analyses, our conclusions are derived from protein abundance, interactions and signaling changes. Protein and mRNA expression do not always correlate well [73,74], but we do not rule out transcriptional mechanisms. Although our data identify the interactions among PARP1, MSH6 and CHAF1A and illustrate the functional effects of MSH6 on CHAF1A protein levels and PARPi sensitivity, the precise mechanistic relationship among these proteins remains to be defined. It is currently unclear whether MSH6 directly regulates CHAF1A activity or whether CHAF1A also contributes to modulating PARPi response. Further functional studies, including rescue experiments and targeted perturbation approaches, will be required to clarify these signaling mechanisms in detail. A limitation of the present study is that it is primarily based on established ovarian cancer cell line models. Therefore, further validation experiments will also have to be performed in patient-derived,xenografts (PDX) and organoids (PDO), as well as clinical tumor specimens to establish its translational relevance and potential clinical applicability. In particular, evaluation of MSH6/PARP1 co-expression in larger clinical cohorts will be required to determine its potential utility as a predictive biomarker for PARPi response. Future studies would be required to validate these findings in vivo and explore the role of post-translational modifications in regulating CHAF1A function. Clinical trials combining PARPis with mTOR or S6K inhibitors in BRCA-proficient ovarian cancer may offer a promising strategy to expand the benefit of PARP inhibitors to a broader patient population. Supporting information Figures S1–S4. (PDF) Original uncropped and unadjusted blot/gel images underlying the results reported in the manuscript and Supporting Information figures. (PDF) Chemical proteomics. (XLSX) ADP-ribosylation proteomics. (XLSX) 13 May 2026 Dear Dr. Deng, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== Based on the reviewers’ comments, the manuscript appears scientifically solid, technically rigorous, and potentially impactful, with strengths in the proteomics workflow and translational relevance. However, both reviewers raise several substantive concerns regarding mechanistic validation, interpretation, and clinical relevance that require additional discussion and likely textual revision rather than extensive new experimentation. Although some reviewers suggest additional mechanistic experiments (e.g., CHAF1A rescue, PARylation site validation, in vivo/organoid validation), these are framed more as desirable strengthening experiments than essential requirements for supporting the current conclusions. ============================== Please submit your revised manuscript by Jun 27 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Giovanni Nassa, PhD Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed: Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer - 10.1016/j.jbc.2022.102550 In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed. 3. Thank you for stating in your Funding Statement: [This project was supported by a Hearing the Ovarian Cancer Whisper Jacquie Liggett Fellowship (to O.D.), the Sarasota foundation fund (to A. N. M.) and the NIH/NCI R21 CA252373 (to A. N. M. and U. R.). Moffitt’s Proteomics & Metabolomics, Molecular Genomics and Chemical Biology Cores are funded in part by the National Cancer Institute through the Cancer Center Support Grant (P30-CA076292), which confers Moffitt’s status as a comprehensive cancer center.]. Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf. 4. Please remove any funding-related text from the manuscript. Please note that funding information should not appear in any section or other areas of your manuscript. We will publish the funding statement that is present in the Financial Disclosure section of the online submission form. 5. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions. 5. Please upload a new copy of Figure 1-6 as the detail is not clear. Please follow the link for more information: https://journals.plos.org/plosone/s/figures 6. Please include captions for all your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: The manuscript is interesting and provides useful insights into mechanisms of PARPi sensitivity in BRCA-proficient ovarian cancer. The proteomics analysis is a clear strength of the study. The work is generally well performed, but several points could be clarified to further strengthen the manuscript. Main Comments 1. All experiments were performed in cell lines. This limitation should be discussed more clearly. Validation in xenograft, organoid, or patient-derived models would further support the translational relevance of the findings, if feasible. 2. The connection between MSH6 and CHAF1A is interesting, but currently appears mostly correlative. The manuscript would benefit from additional discussion of: MSH6 regulates CHAF1A directly, CHAF1A is required for MSH6-related PARPi rescue experiments were considered or attempted. 3. The decrease in CHAF1A ADP-ribosylation is interesting, but it is not fully clear whether this reflects a specific mechanism or broader changes in PARP activity. Some mechanistic conclusions may need to be stated more cautiously. 4. The classification of “sensitive” and “resistant” based mainly on rucaparib Cmax may oversimplify biological differences between models. Additional discussion of HRD status, replication stress, genomic instability, or published PARPi response data would strengthen the interpretation. 5. Since MSH6 is an important mismatch repair protein, the Discussion should more fully address mismatch repair deficiency, microsatellite instability, and their possible relationship with PARPi response. 6. More detail on statistical analysis would improve clarity, including: multiple testing correction, exact p-values or effect sizes, and justification of proteomics filtering thresholds. Minor Comments 1. Some figure legends are too long and could be simplified. 2. In several places, associative wording may be more appropriate than causal wording. 3. The Discussion would benefit from additional comparison with previous studies on PARP1, mismatch repair, and replication fork stability. 4. Minor grammar and formatting issues should be corrected. 5. Abbreviations should be used consistently throughout the manuscript. Questions for the Authors 1. Were rescue experiments with CHAF1A restoration considered or performed? 2. Are there public datasets linking MSH6 expression with PARPi response in BRCA-proficient ovarian cancer? 3. Have the authors considered validation in organoid or in vivo models? 4. Did the authors examine HR-related markers such as RAD51 foci after MSH6 depletion? 5. How did the authors distinguish specific PARylation effects from global PARP inhibition effects? Overall Assessment Overall, this is a strong and potentially impactful study. The manuscript would be further improved by additional clarification, expanded discussion of limitations, and more cautious interpretation of mechanistic conclusions. Reviewer #2: The study investigated the mechanisms of PARP inhibitor (PARPi) sensitivity in BRCA-proficient ovarian cancer. The methods are sophisticated and appropriate. The multi-platform proteomic workflow combined with molecular biological validation is a major strength and appears technically rigorous. Data supports the conclusion. The identification of a PARP1/MSH6/CHAF1A-associated network linked to PARPi sensitivity is potentially novel and clinically relevant. Given the need for biomarkers for PARPi responses beyond BRCA deficiency, this research is highly interesting. There are a few comments that need to be discussed. In the survival analysis (Fig 4), stratified analysis in patients receiving platinum and taxol based chemotherapy were analyzed. How about patients receiving PARPi? Is MSH6 related to clinical outcomes of patients receiving PAPRi? The proposed role of CHAF1A PARylation is largely associative. Direct evidence is lacking demonstrating functional dependence on CHAF1A PARylation sites. The translational relevance is promising but a bit overstated. Claims regarding biomarker potential for MSH6 and PARP1 should be tempered because patient survival analyses are modest and largely indirect. Overall, this is a strong and potentially impactful study, but additional mechanistic validation and more cautious interpretation are needed before publication in a high-impact setting. A minor comment: Line 296-297: “…only rucaparib was FDA-approved as maintenance therapy for recurrent OC regardless of BRCA mutation status” is not accurate. For example, niraparib also is FAD-approved for maintenance therapy regardless of BRCA/HRD status. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Raikhan Bolatbekova Reviewer #2: Yes: Qi Chen ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 6 Jul 2026 Response to Academic Editor General Editorial Assessment Comment: The manuscript appears scientifically solid, technically rigorous, and potentially impactful, with strengths in the proteomics workflow and translational relevance. However, several concerns were raised regarding mechanistic validation, interpretation, and clinical relevance, which require additional discussion and textual revision. Response: We sincerely thank the Academic Editor for the positive evaluation of our work and for the constructive guidance. In response to these concerns, we substantially revised the manuscript to strengthen the discussion of mechanistic validation, clarify interpretation of the findings, and better contextualize the clinical relevance of the study. Specifically, we: Expanded the Discussion section regarding mechanistic implications and limitations; Clarified the interpretation of the proteomics findings; Added discussion addressing the suggested future validation experiments, including CHAF1A rescue studies, PARylation site validation, and in vivo/organoid validation approaches. These revisions are reflected throughout the revised manuscript. Journal Requirements Comment 1 Please ensure that your manuscript meets PLOS ONE style requirements, including file naming and formatting. Response: We carefully revised the manuscript to comply with all PLOS ONE formatting and file naming requirements. Comment 2 We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed: Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer - 10.1016/j.jbc.2022.102550 In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed. Response: We thank the editor for bringing this to our attention. We carefully reviewed our manuscript in comparison with the cited publication (DOI: 10.1016/j.jbc.2022.102550), which was already cited in the Introduction: “In our previous work, we have observed that the composition of PARP1-associated protein complexes and patterns of poly-ADP-ribosylation (PARylation) may play critical roles in differentially modulating PARPi response between BRCA-deficient and BRCA-proficient OC cells [20].” In addition, we reviewed the manuscript for potential text overlap outside the Methods section and revised the wording where appropriate. We have also verified that all relevant prior work, including our own publications, is properly cited throughout the manuscript. Comment 3 Please amend the Funding Statement and include: “There was no additional external funding received for this study.” Response: We updated the Funding Statement to include all funding sources and added the requested statement: “There was no additional external funding received for this study.” Comment 4 Please remove funding-related text from the manuscript. Response: All funding-related text has been removed from the manuscript body in accordance with PLOS ONE guidelines. Comment 5 Please provide original uncropped and unadjusted blot/gel images. Response: We have provided the original uncropped and unadjusted blot/gel images as Supporting Information files, in accordance with PLOS ONE figure reporting requirements. Comment 6 Please upload higher-quality versions of Figures 1–6. Response: We uploaded revised high-resolution versions of Figures 1–6 to improve image clarity and readability. Comment 7 Please include captions for all Supporting Information files and update in-text citations accordingly. Response: Captions for all Supporting Information files have been added at the end of the manuscript, and all in-text citations have been updated accordingly. Response to Reviewer #1 Main Comments Comment 1 All experiments were performed in cell lines. This limitation should be discussed more clearly. Validation in xenograft, organoid, or patient-derived models would further support the translational relevance of the findings, if feasible. Response: We appreciate the reviewer’s insightful comment and agree that validation in organoid, xenograft, or patient-derived models would further strengthen the translational relevance of our findings. We have therefore revised the Discussion section to explicitly acknowledge this limitation and emphasize the importance of future validation in physiologically relevant systems. Accordingly, we have added this aspect to the discussion: “A limitation of the present study is that it is primarily based on established ovarian cancer cell line models. Therefore, further validation experiments will also have to be performed in patient-derived organoids, xenografts, and clinical tumor specimens to establish its translational relevance and potential clinical applicability.” (Page 32) Comment 2 The connection between MSH6 and CHAF1A is interesting, but currently appears mostly correlative. The manuscript would benefit from additional discussion of: MSH6 regulates CHAF1A directly, CHAF1A is required for MSH6-related PARPi rescue experiments were considered or attempted. Response: We appreciate this important observation. In the revised manuscript, we toned down mechanistic interpretations regarding the relationship between MSH6 and CHAF1A and clarified that our current findings support a functional association rather than definitive direct regulation. We further expanded the Discussion to acknowledge that the precise mechanistic relationship between MSH6 and CHAF1A remains to be established, and that rescue experiments and targeted mechanistic validation would be valuable future directions to clarify the functional hierarchy within this pathway and to define its contribution to PARPi sensitivity in BRCA-proficient ovarian cancer. Accordingly, we have added this to the discussion: “Although our data identify the pair-wise interactions between PARP1, MSH6 and CHAF1A and illustrate the functional effects of MSH6 on CHAF1A protein levels and PARPi sensitivity, the precise mechanistic relationship between these proteins remains to be defined. It is currently unclear whether MSH6 directly regulates CHAF1A activity or whether CHAF1A also contributes to modulating PARPi response. Further functional studies, including rescue experiments and targeted perturbation approaches, will be required to clarify these signaling mechanisms in detail.” (Page 32) Comment 3 The decrease in CHAF1A ADP-ribosylation is interesting, but it is not fully clear whether this reflects a specific mechanism or broader changes in PARP activity. Response: We agree that the observed decrease in CHAF1A ADP-ribosylation should be interpreted cautiously. Our study was designed to compare ADP-ribosylation profiles between PARPi-sensitive and -resistant cells. Following rucaparib treatment, we observed a significant reduction in CHAF1A ADP-ribosylation, and CHAF1A emerged as one of the proteins exhibiting differential ADP-ribosylation between PARPi-sensitive and -resistant cells. Considering the pronounced effects of CHAF1A silencing on cell viability, these findings suggest that CHAF1A may represent a downstream target associated with PARP1 signaling and PARPi response. However, future studies will be important to determine the extent to which CHAF1A ADP-ribosylation contributes to PARPi sensitivity and therapeutic response. Additional mechanistic studies, including PARP1 knockout or depletion models, biochemical validation of CHAF1A ADP-ribosylation, and site-specific ADP-ribosylation analyses, will be required to further investigate the regulation of CHAF1A ADP-ribosylation. Accordingly, we have revised the Discussion to tone down the mechanistic interpretation and clarify these limitations: “These findings indicate that CHAF1A ADP-ribosylation is associated with PARPi response and may contribute to the differential assembly of the PARP1/MSH6/CHAF1A complex. However, whether CHAF1A is directly ADP-ribosylated by PARP1 or other known PARP family targets, such as PARP2 or tankyrase [37, 68], ADP-ribosylation occurs at specific functional sites or contributes directly to CHAF1A’s regulatory activity requires further studies using PARP1 knockdown, site-directed mutagenesis and mapping of CHAF1A PARylation sites.” (Page 30) “However, the functional consequences of CHAF1A ADP-ribosylation, its impact on protein interactions and PARPi response were not examined in this study and will require further investigation.” (Page 31) Comment 4 The classification of “sensitive” and “resistant” based mainly on rucaparib Cmax may oversimplify biological differences between models. Response: We appreciate the reviewer’s concern. However, the classification of PARPi-sensitive and -resistant models was not based solely on rucaparib Cmax. PARPi sensitivity was evaluated according to the IC50 values of all three FDA-approved PARPis across the BRCA-proficient ovarian cancer cell lines. As described in Results section 1, we focused on rucaparib because it is the PARPi FDA-approved for recurrent ovarian cancer regardless of BRCA status. At the clinically relevant Cmax (1.94 μM), only about one-third of the tested cell lines showed >50% reduction in viability, while most exhibited limited response. Based on these response patterns, we selected A2780, OVCAR8, and Caov3 as representative PARPi-sensitive lines and HEYA8, SKOV3, and OVCA432 as PARPi-resistant lines (Fig. 1B). OVCAR3 was excluded despite its sensitivity because of previously reported deep BRCA2 deletions, which could confound interpretation of BRCA-proficient PARPi responses. We have now rewritten this sentence to reflect the sensitivity/resistance to the other PARPis more clearly, now reads (changes in bold): “Based on their IC50 values, relative to rucaparib’s maximal plasma concentration (1.94 mM), and consistency across the other PARPis olaparib and niraparib, cell lines were classified as sensitive or resistant (Fig 1B).” (Page 14) Comment 5 Since MSH6 is an important mismatch repair protein, the Discussion should more fully address mismatch repair deficiency, microsatellite instability, and their possible relationship with PARPi response. Response: We thank the reviewer for this important suggestion. We agree that MSH6 is a core component of the DNA mismatch repair (MMR) pathway and is frequently discussed in the context of mismatch repair deficiency and microsatellite instability (MSI), which have been associated with genome instability and therapeutic responses in cancer. However, MSI-high ovarian cancers are relatively uncommon, and the majority of ovarian cancers, including the models used in our study, are microsatellite stable (MSS). Therefore, the biological context of our study differs from that of MSI-associated malignancies in which MSH6 dysfunction has been more extensively investigated. Previous studies investigating MSH6 in the context of PARP inhibitor response have largely focused on MMR deficiency, MSI, or genetic alterations of MMR pathway components. In contrast, the ovarian cancer models examined in the present study are predominantly microsatellite stable (MSS) and BRCA-proficient. Therefore, our findings relate to differential MSH6 protein expression and protein complex formation rather than classical MMR deficiency. To our knowledge, the association between MSH6 protein expression and PARP inhibitor sensitivity in BRCA-proficient ovarian cancer has not been systematically investigated. We have revised the Discussion to explicitly acknowledge the canonical role of MSH6 in MMR and its established relationship with MSI. However, our experimental findings suggest that MSH6 may also have functions beyond its traditional role in mismatch repair. Notably, depletion of MSH6 did not significantly affect cell viability, indicating that the observed effects are unlikely to be explained solely by loss of canonical MMR activity. Instead, our data supports a model in which MSH6 contributes to PARP inhibitor response through altered protein interactions, including changes in PARP1-associated complexes and downstream signaling pathways. Nevertheless, the precise mechanisms linking MSH6 expression to PARP inhibitor sensitivity remain to be fully elucidated and warrant further investigation. These revisions have been incorporated into the Discussion: “MSH6 has been extensively studied in the context of MMR deficiency and microsatellite instability (MSI) [57-60]. However, MSI-high tumors are relatively uncommon in ovarian cancer, occurring in approximately 1–3% of serous cases [61-65]. Although MSI status was not directly assessed in the present study, previous reports have classified SKOV3 as MSI-H, whereas the remaining cell lines used in this study are generally considered microsatellite stable (MSS) [66, 67]. Therefore, the differential MSH6 expression and PARP1/MSH6 complex formation observed in our models are unlikely to be explained solely by classical MMR deficiency. Instead, these findings support the possibility that MSH6 may have additional functions beyond canonical mismatch repair, potentially through PARP1-associated signaling pathways that influence PARPi response. The relationship between MSH6-associated signaling, MSI phenotypes, and PARPi sensitivity warrants further investigation.” (Page 29-30) Comment 6 More detail on statistical analysis would improve clarity. Response: Additional details regarding statistical analyses have now been included in the Methods section: “Data was obtained from at least three independent experiments and shown as the mean ± SD. Data was analyzed using Microsoft Excel and GraphPad Prism 10.0. Statistical analyses were performed using Student’s t test (paired or unpaired, as appropriate) and synergy was determined by the Bliss independence model[35]. P value of <0.05 was considered statistically significant. All statistical details are included in the figure legends. All MaxQuant data were first filtered for peptides with PEP score < 0.05. Furthermore, reverse and contaminant peptides and peptides with no intensity were excluded. Data were then normalized using IRON[41].” (Page 13) Minor Comments 1. Some figure legends are too long and could be simplified. 2. In several places, associative wording may be more appropriate than causal wording. 3. The Discussion would benefit from additional comparison with previous studies on PARP1, mismatch repair, and replication fork stability. 4. Minor grammar and formatting issues should be corrected. 5. Abbreviations should be used consistently throughout the manuscript. Response: We thank the reviewer for these suggestions. Figure legends were revised for clarity and conciseness, causal wording was modified where appropriate, additional literature comparisons were incorporated into the Discussion, and the manuscript was carefully edited for grammar, formatting consistency, and standardized abbreviation usage throughout. Questions for the Authors Question 1 Were rescue experiments with CHAF1A restoration considered or performed? Response: We agree that such experiments would provide important mechanistic validation and would have liked to engage in these experiments: “A limitation of the present study is that it is primarily based on established ovarian cancer cell line models. Therefore, further validation experiments will also have to be performed in patient-derived organoids, xenografts, and clinical tumor specimens to establish its translational relevance and potential clinical applicability.” (Page 32) Question 2 Are there public datasets linking MSH6 expression with PARPi response in BRCA-proficient ovarian cancer? Response: To the best of our knowledge, as PARPis have been approved for ovarian cancer only for a few years so far and not as first-line therapy, there are currently no large, dedicated public clinical datasets that directly stratify PARPi response by MSH6 expression specifically in BRCA-proficient ovarian cancer cohorts. Question 3 Have the authors considered validation in organoid or in vivo models? Response: Yes. We agree that validation in organoid and in vivo systems would substantially st Submitted filename: Response to Reviewers.pdf 29 Jul 2026 Dear Dr. Deng, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 12 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Giovanni Nassa, PhD Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: Overall, now the manuscript is a well-conducted and impactful study. Only a few minor points require clarification to further strengthen the mechanistic interpretation and improve the manuscript's clarity as requested by R1. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: I Don't Know ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: The study addresses a critical clinical challenge in gynecologic oncology: expanding PARP inhibitor (PARPi) utility to BRCA-proficient tumors. The multi-omics framework—coupling chemical proteomics (rucaparib pull-downs) with ADP-ribosylation proteomics—is innovative and technically robust. Primary Conceptual Gap: The mechanistic transition between MSH6 loss and mTOR activation needs clearer bridging. The text posits that CHAF1A acts downstream of MSH6 to regulate mTOR, but the exact mechanism remains speculative. Clarify this boundary in the Discussion. Title & Abstract Clear, well-structured, and accurately reflects the scope of the manuscript. Introduction Line 74–75: Clarify the criteria for "BRCA-proficient" upfront (e.g., absence of somatic/germline pathogenic mutations and functional HR proficiency where validated). Materials and Methods Line 88: Standardize cell line naming: ensure consistency between HEAYA8 (Line 85), HEAY8 (Line 353), and HEYA8 (used elsewhere). Standardize to HEYA8 across all sections Results Selecting A2780, OVCAR8, and Caov3 as sensitive lines versus HEYA8, SKOV3, and OVCA432 as resistant lines is well-justified. A2780 is widely acknowledged as an endometrioid/undifferentiated line rather than classic high-grade serous ovarian carcinoma (HGSOC). While acceptable for general BRCA-proficient OC modeling, add a brief parenthetical note or statement in the Discussion clarifying cell line histotypes. Highlight the novelty of MSH6 enrichment over MSH2, which suggests an unconventional MMR-independent assembly. Discussion Consider adding a concise summary paragraph at the start of the Discussion that explicitly contrasts sensitive versus resistant states: Sensitive cells: High MSH6 → PARP1–MSH6–CHAF1A complex intact → PARP1 inhibition reduces CHAF1A PARylation → suppression of mTOR signaling → cell death/synthetic lethality. Resistant cells: Low MSH6 / complex dissociation → elevated CHAF1A → compensatory mTORC1 pathway activation → survival (targetable with mTOR/S6K inhibitors). Study Limitations: Expand slightly on the limitations, specifically noting the need for future in vivo PDX/allograft validation and broader clinical cohort verification for MSH6/PARP1 co-expression as a predictive biomarker. Reviewer #2: The authors have addressed all previously critiques. There is no additional comments. I recommend acceptance for publication. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: Qi Chen ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 14 Aug 2026 Response to Reviewer #1 We sincerely thank the reviewer for the thoughtful and constructive comments. We appreciate the positive assessment of our study and have revised the manuscript accordingly. Our point-by-point responses are provided below. Comment 1. The mechanistic transition between MSH6 loss and mTOR activation needs clearer bridging. The text posits that CHAF1A acts downstream of MSH6 to regulate mTOR, but the exact mechanism remains speculative. Clarify this boundary in the Discussion. Response: We thank the reviewer for this important comment. We agree that the mechanistic relationship between MSH6 loss, CHAF1A regulation, and mTOR activation remains incompletely defined. We have revised the Discussion to clarify this mechanistic boundary. The revised text now reads: “These findings link MSH6, probably through modulation of CHAF1A–mTOR signaling, to PARPi resistance in BRCA-proficient OC. However, whether and how CHAF1A is directly regulated by MSH6 or serves as a critical mediator connecting MSH6 loss to mTOR activation remains to be determined.” (Page 31) Comment 2. Line 74–75: Clarify the criteria for "BRCA-proficient" upfront (e.g., absence of somatic/germline pathogenic mutations and functional HR proficiency where validated). Response: We thank the reviewer for this suggestion. We have clarified the criteria for "BRCA-proficient" in the Introduction. The revised text now reads: “In this study, we investigated the proteomic landscape associated with PARPi sensitivity in a diverse panel of BRCA-proficient OC cell lines, defined here by the absence of BRCA1/2 mutations or genomic deletions. Most cell lines used in this study have previously been reported to exhibit HR proficiency [21-24].” (Page 4) Comment 3. Line 88: Standardize cell line naming: ensure consistency between HEAYA8 (Line 85), HEAY8 (Line 353), and HEYA8 (used elsewhere). Standardize to HEYA8 across all sections Response: We thank the reviewer for identifying this inconsistency. The manuscript has been carefully reviewed, and all instances have been corrected to the standardized cell line name, HEYA8, throughout the manuscript. Comment 4. Results Selecting A2780, OVCAR8, and Caov3 as sensitive lines versus HEYA8, SKOV3, and OVCA432 as resistant lines is well-justified. A2780 is widely acknowledged as an endometrioid/undifferentiated line rather than classic high-grade serous ovarian carcinoma (HGSOC). While acceptable for general BRCA-proficient OC modeling, add a brief parenthetical note or statement in the Discussion clarifying cell line histotypes. Response: We appreciate this important comment. A brief statement has been added to the Discussion acknowledging that A2780 is an endometrioid/undifferentiated ovarian cancer cell line. The revised text now reads: “To further investigate the mechanisms underlying PARPi sensitivity and resistance, we employed chemical proteomics and ADP-ribosylation proteomics to examine PARP1 protein complexes and PARylation profiles in PARPi-sensitive and -resistant BRCA-proficient OC cells, including the endometrioid OC cell line A2780.” (Page 28) Comment 5. Highlight the novelty of MSH6 enrichment over MSH2, which suggests an unconventional MMR-independent assembly. Response: We thank the reviewer for this insightful comment. We agree that the selective enrichment of MSH6 over MSH2 represents an important observation of our study. We have revised the Discussion to further emphasize the potential significance of this finding. The revised text now reads: “Although PARP1 and MSH6 have been previously reported to interact during mismatch repair (MMR)[55, 56], particularly during the recognition and signaling of DNA mismatches, our chemical proteomics data demonstrated selective enrichment of PARP1/MSH6 complexes in PARPi-sensitive cells with no apparent enrichment of MSH2. This finding suggests an unconventional, potentially MMR-independent role for MSH6 in modulating PARPi sensitivity.” (Page 29) Comment 6. Discussion Consider adding a concise summary paragraph at the start of the Discussion that explicitly contrasts sensitive versus resistant states: Sensitive cells: High MSH6 → PARP1–MSH6–CHAF1A complex intact → PARP1 inhibition reduces CHAF1A PARylation → suppression of mTOR signaling → cell death/synthetic lethality. Resistant cells: Low MSH6 / complex dissociation → elevated CHAF1A → compensatory mTORC1 pathway activation → survival (targetable with mTOR/S6K inhibitors). Response: We appreciate this suggestion. We have added a concise summary paragraph at the beginning of the Discussion. The new paragraph summarizes the differences in MSH6-associated PARP1 complex formation, CHAF1A ADP-ribosylation and expression, mTOR signaling, and cellular response to rucaparib, and highlights the potential therapeutic relevance of mTOR pathway inhibition in PARPi-resistant cells. “Overall, our findings support a model in which PARPi-sensitive and PARPi-resistant BRCA-proficient OC cells exhibit distinct PARP1-associated protein complexes and downstream signaling. PARPi-sensitive compared to PARPi-resistant cells preferentially featured a PARP1-MSH6-CHAF1A complex and higher CHAF1A ADP-ribosylation, reduced by PARPi treatment, which prevented cells to launch PARPi-adaptive mTOR survival signaling. In contrast, PARPi-resistant cells showed compensatory activation of mTOR signaling following PARPi treatment and enhancement of rucaparib effects by pharmacological inhibition of the mTOR pathway. These findings suggest that compensatory mTOR signaling contributes to PARPi resistance and that mTOR pathway inhibition may be a potential combination strategy for PARPi-resistant cells.” (Page 28) Comment 7. Study Limitations: Expand slightly on the limitations, specifically noting the need for future in vivo PDX/allograft validation and broader clinical cohort verification for MSH6/PARP1 co-expression as a predictive biomarker. Response: We thank the reviewer for this valuable suggestion. We have expanded the Limitations section to further acknowledge the need for in vivo validation and evaluation of MSH6/PARP1 co-expression as a predictive biomarker for PARPi response. The revised text now reads: “A limitation of the present study is that it is primarily based on established ovarian cancer cell line models. Therefore, further validation experiments will also have to be performed in patient-derived xenografts (PDX) and organoids (PDO), as well as clinical tumor specimens to establish its translational relevance and potential clinical applicability. In particular, evaluation of MSH6/PARP1 co-expression in larger clinical cohorts will be required to determine its potential utility as a predictive biomarker for PARPi response.” (Page 32) Submitted filename: Response_to_Reviewers_auresp_2.pdf 17 Aug 2026 Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer PONE-D-26-10571R2 Dear Dr. Deng, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Giovanni Nassa, PhD Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: PONE-D-26-10571R2 PLOS One Dear Dr. Deng, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS One and supporting open access. Kind regards, PLOS One Editorial Office Staff on behalf of Dr. Giovanni Nassa Academic Editor PLOS One